Stock-Based Compensation for ResMed (RMD)
Stock-Based Compensation for ResMed (RMD): headline value $98.97M · YoY +14.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
RMD
Currently viewingStock-Based CompensationSwitch metric
Latest period
$98.97M
YoY change
+14.3%
5Y CAGR
+9.8%
Peak year (2025)
$91.66M
Latest annual
$91.66M
Stock-Based Compensation history chart for ResMed (RMD) from 1993 to 2025
Stock-Based Compensation history table for ResMed (RMD) from 1993 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $91.66M | +14.3% | ||
| 2024 | $80.18M | +12.7% | ||
| 2023 | $71.14M | +9.0% | ||
| 2022 | $65.26M | +2.1% | ||
| 2021 | $63.93M | +11.1% | ||
| 2020 | $57.56M | +10.5% | ||
| 2019 | $52.07M | +7.6% | ||
| 2018 | $48.41M | +5.4% | ||
| 2017 | $45.92M | -1.0% | ||
| 2016 | $46.41M | -3.0% | ||
| 2015 | $47.85M | +10.1% | ||
| 2014 | $43.46M | +13.9% | ||
| 2013 | $38.16M | +24.8% | ||
| 2012 | $30.59M | -0.7% | ||
| 2011 | $30.81M | +3.6% | ||
| 2010 | $29.73M | +16.5% | ||
| 2009 | $25.52M | — | ||
| 2008 | $0 | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — |
Stock-Based Compensation values are taken from ResMed's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, ResMed (RMD) reported stock-based compensation of $91.66M – grew 14.3% year-over-year.
Through 2020–2025 (5 years), ResMed stock-based compensation delivered a +9.8% annualised rate; with the latest reading among the more recent periods of the dataset.
Across the available history, stock-based compensation reached its high of $91.66M in 2025 and its low of $0 in 1993.
Among 8 Healthcare peers, ResMed (RMD) ranks 5th; the peer median for stock-based compensation is $313.00M.
ResMed Stock-Based Compensation by Year
ResMed Stock-Based Compensation 2025: $91.66M
ResMed stock-based compensation in 2025 was $91.66M, grew 14.3% from 2024. This figure represents the highest annual value in the available history.
ResMed Stock-Based Compensation 2024: $80.18M
ResMed stock-based compensation in 2024 was $80.18M, grew 12.7% from 2023.
ResMed Stock-Based Compensation 2023: $71.14M
ResMed stock-based compensation in 2023 was $71.14M, grew 9.0% from 2022.
ResMed Stock-Based Compensation 2022: $65.26M
ResMed stock-based compensation in 2022 was $65.26M, edged up 2.1% from 2021.
ResMed Stock-Based Compensation 2021: $63.93M
ResMed stock-based compensation in 2021 was $63.93M.
See more financial history for ResMed (RMD).
Sector peers — Stock-Based Compensation
Companies in the same sector as ResMed, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is ResMed's stock-based compensation?
Latest reported stock-based compensation for ResMed (RMD) is $98.97M (period ending December 31, 2025).
How has ResMed stock-based compensation changed year-over-year?
ResMed (RMD) stock-based compensation changed +14.3% year-over-year on the latest annual filing.
What is the long-term growth rate of ResMed stock-based compensation?
ResMed (RMD) stock-based compensation compound annual growth rate is +9.8% over the most recent 5 years available.
When did ResMed stock-based compensation hit its highest annual value?
ResMed stock-based compensation reached its highest annual value of $91.66M in 2025.
What was ResMed stock-based compensation in 2024?
ResMed (RMD) stock-based compensation in 2024 was $80.18M.
What was ResMed stock-based compensation in 2025?
ResMed (RMD) stock-based compensation in 2025 was $91.66M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
RMD Overview
Company profile, financial tools, and key metrics
RMD Revenue Counter
Earns $171.17 every second. See per minute, hour, and day.
RMD Earnings Counter
Earns $47.12 per second net profit. See per minute, hour, and day.
RMD Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
RMD What If Invested
What if you had invested $1,000? See historical returns from any date.
RMD How It Makes Money
Discover visual breakdown of $5.40B in revenue — where it comes from and where it goes.
RMD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
RMD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
RMD Daily Price Character
Balanced · 50.4% historical win rate (green days). Streaks & record days.
RMD Buybacks
1.42% TTM buyback yield. Shareholder yield & SBC comparison.
RMD Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.
RMD Dividend Profile
Yield: 1.10%. Safety: 6/8. See full history.
RMD Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
RMD Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.